Thomas Thum

Thomas Thum is a physician-scientist, entrepreneur and Director of the Institute of Molecular and Translational Therapeutic Strategies at Hannover Medical School. His research focuses on RNA therapeutics, cardiovascular disease, fibrosis and regenerative medicine. He founded Cardior Pharmaceuticals and led the development of one of the world’s most advanced microRNA-based therapies for heart failure, culminating in its acquisition by Novo Nordisk in 2024. He has authored more than 500 scientific publications and holds numerous patents.